TEM - Tempus AI, Inc. Последние новости | Finranks

16.06.2026

Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms

Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with breakout resistance at $54.75 and a first target near $64.54.

11.06.2026

Tempus AI: AI Precision Medicine With A Moat

Tempus AI trades at multi-year lows despite proprietary data advantages and robust AI-driven precision medicine capabilities. The company leverages 500+ petabytes of unique multimodal healthcare data inaccessible to generic AI models. With a market cap under $9B and trading at ~4.5x forward sales, the stock's valuation is compelling given management's 25% annual growth target versus more conservative analyst estimates.

11.06.2026

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled "Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Fl.

09.06.2026

Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy

Tempus AI (TEM) now offers an attractive risk-reward setup, with valuations normalized to ~5.7x forward revenue and improved visibility on durable, high-margin revenues. Organic growth remains robust at ~25% for 2026, with no adverse revisions for 2027–2028, and margin mix shifting toward higher-margin Data and Applications segments. Adjusted operating loss has narrowed significantly, and TEM is approaching operating breakeven, supporting the SaaS-like trajectory critical for long-term value.

09.06.2026

Tempus AI: A Unique AI Business Model With Asymmetric Upside

Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding gross margins and deepening pharma partnerships. Massive proprietary datasets (45M+ de-identified records, 500+ PB) underpin AI tools, SaaS revenue, and cross-selling opportunities, creating high barriers to entry.

09.06.2026

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, published in Genetics in Medicine Open, showcases how targeted RNA analysis using Ambry's ExomeReveal workflow; an in.

08.06.2026

Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Видео

08.08.2025

Positive

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
TEM	BTIG Research	Buy	undefined >> $60	April 21st 2025
TEM	JP Morgan	Neutral	$50 >> $55	February 25th 2025
TEM	William Blair	Market Perform	undefined >> undefined	February 12th 2025

Пресс-релизы

11.06.2026

Tempus AI, Inc. (TEM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tempus AI, Inc. (TEM)

Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms

Tempus AI: AI Precision Medicine With A Moat

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy

Tempus AI: A Unique AI Business Model With Asymmetric Upside

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing